Belite Bio (BLTE) Competitors $76.97 +1.37 (+1.81%) As of 11:11 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLTE vs. RVMD, GRFS, RYTM, LEGN, ABVX, RNA, CYTK, AXSM, CRSP, and NUVLShould you be buying Belite Bio stock or one of its competitors? The main competitors of Belite Bio include Revolution Medicines (RVMD), Grifols (GRFS), Rhythm Pharmaceuticals (RYTM), Legend Biotech (LEGN), Abivax (ABVX), Avidity Biosciences (RNA), Cytokinetics (CYTK), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), and Nuvalent (NUVL). These companies are all part of the "pharmaceutical products" industry. Belite Bio vs. Its Competitors Revolution Medicines Grifols Rhythm Pharmaceuticals Legend Biotech Abivax Avidity Biosciences Cytokinetics Axsome Therapeutics CRISPR Therapeutics Nuvalent Revolution Medicines (NASDAQ:RVMD) and Belite Bio (NASDAQ:BLTE) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation. Which has more volatility and risk, RVMD or BLTE? Revolution Medicines has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500. Comparatively, Belite Bio has a beta of -1.46, meaning that its stock price is 246% less volatile than the S&P 500. Do analysts rate RVMD or BLTE? Revolution Medicines currently has a consensus price target of $74.64, indicating a potential upside of 58.81%. Belite Bio has a consensus price target of $96.00, indicating a potential upside of 24.72%. Given Revolution Medicines' stronger consensus rating and higher probable upside, equities analysts plainly believe Revolution Medicines is more favorable than Belite Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revolution Medicines 1 Sell rating(s) 0 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.93Belite Bio 1 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is RVMD or BLTE more profitable? Belite Bio's return on equity of -34.90% beat Revolution Medicines' return on equity.Company Net Margins Return on Equity Return on Assets Revolution MedicinesN/A -41.78% -35.63% Belite Bio N/A -34.90%-33.56% Do insiders and institutionals believe in RVMD or BLTE? 94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 0.5% of Belite Bio shares are owned by institutional investors. 8.2% of Revolution Medicines shares are owned by insiders. Comparatively, 13.3% of Belite Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has preferable earnings & valuation, RVMD or BLTE? Belite Bio has lower revenue, but higher earnings than Revolution Medicines. Belite Bio is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRevolution Medicines$11.58M758.73-$600.09M-$4.50-10.44Belite BioN/AN/A-$36.14M-$1.55-49.66 Does the media prefer RVMD or BLTE? In the previous week, Revolution Medicines had 5 more articles in the media than Belite Bio. MarketBeat recorded 6 mentions for Revolution Medicines and 1 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.80 beat Revolution Medicines' score of 0.79 indicating that Belite Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryRevolution Medicines beats Belite Bio on 9 of the 15 factors compared between the two stocks. Get Belite Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BLTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLTE vs. The Competition Export to ExcelMetricBelite BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.45B$3.36B$6.12B$10.57BDividend YieldN/A2.28%5.66%4.70%P/E Ratio-49.6622.2286.0827.08Price / SalesN/A268.80534.29204.46Price / CashN/A46.3226.3031.09Price / Book16.319.9712.726.66Net Income-$36.14M-$52.35M$3.30B$275.86M7 Day Performance5.44%6.36%4.34%3.06%1 Month Performance17.08%12.02%7.82%10.52%1 Year Performance50.95%26.08%73.82%33.54% Belite Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLTEBelite Bio3.0135 of 5 stars$76.97+1.8%$96.00+24.7%+48.3%$2.45BN/A-49.6610Positive NewsRVMDRevolution Medicines4.286 of 5 stars$44.41+2.0%$73.67+65.9%-1.3%$8.14B$11.58M-9.87250GRFSGrifols3.6257 of 5 stars$9.70-0.4%$10.30+6.2%+11.5%$6.70B$7.81B8.2923,822Positive NewsShort Interest ↑RYTMRhythm Pharmaceuticals3.5124 of 5 stars$99.00+3.1%$101.57+2.6%+99.5%$6.38B$130.13M-32.89140LEGNLegend Biotech2.8182 of 5 stars$34.08+0.2%$74.22+117.8%-34.7%$6.28B$627.24M-38.732,609ABVXAbivax3.1078 of 5 stars$82.21-0.1%$99.43+20.9%+758.1%$6.22BN/A0.0061RNAAvidity Biosciences2.5668 of 5 stars$42.34+3.1%$68.32+61.4%-0.6%$5.99B$10.90M-11.89190Positive NewsCYTKCytokinetics3.8721 of 5 stars$48.25-0.8%$75.71+56.9%+0.5%$5.82B$18.47M-9.46250Analyst ForecastAXSMAxsome Therapeutics4.7938 of 5 stars$117.49+1.3%$177.86+51.4%+38.9%$5.79B$385.69M-23.17380Analyst RevisionCRSPCRISPR Therapeutics1.6748 of 5 stars$62.10-0.4%$71.50+15.1%+49.3%$5.67B$37.31M-11.44460NUVLNuvalent3.2613 of 5 stars$78.90+2.9%$119.50+51.5%-19.7%$5.53BN/A-16.1040 Related Companies and Tools Related Companies RVMD Alternatives GRFS Alternatives RYTM Alternatives LEGN Alternatives ABVX Alternatives RNA Alternatives CYTK Alternatives AXSM Alternatives CRSP Alternatives NUVL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BLTE) was last updated on 10/6/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"My prediction: Q4 2025 won't just be another seasonal crypto pump. It will be the quarter that sparks a crypto...Crypto 101 Media | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredWall Street legend: “Sell this A.I. stock now”Whats next after AI? Hidden AI. "Hidden AI" could soon be the biggest investment trend of 2025.Chaikin Analytics | SponsoredThe next wave of AI fortunes may come from NVIDIA’s secret supplier.Bloomberg says AI is a $50 trillion revolution. And at the center of it… isn't NVIDIA. It's a tiny suppl...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belite Bio, Inc. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Belite Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
